The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration

Journal of Controlled Release

Volumn 126, Issue 1, 2008, Pages 1-9

  Dahan, Arik ^a   Duvdevani, Revital ^b   Shapiro, Israel ^b   Elmann, Anat ^b   Finkelstein, Elena ^b   Hoffman, Amnon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b D Pharm Ltd   (Israel)

Author keywords

Drug delivery; Food effect; Lymphatic transport; Oral prodrug; Pharmacokinetics; Phospholipase A2; Phospholipid drug conjugate; Valproic acid

Indexed keywords

ABSORPTION; DEGRADATION; ENZYMES; FOOD PRODUCTS; PHARMACOKINETICS; PHOSPHOLIPIDS; RATS;

FOOD EFFECT; LYMPHATIC TRANSPORT; ORAL PRODRUG; PHOSPHOLIPASE A; PHOSPHOLIPID-DRUG CONJUGATES; VALPROIC ACID;

DRUG DELIVERY;

PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2; VALPROIC ACID;

ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; ENZYME DEGRADATION; FOOD INTAKE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DRUG CARRIERS; DRUG STABILITY; FOOD-DRUG INTERACTIONS; INJECTIONS, INTRAVENOUS; LECITHINS; LYMPH; LYMPHATIC VESSELS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR STRUCTURE; MOUTH MUCOSA; PHOSPHOLIPASES A2; POSTPRANDIAL PERIOD; PRODRUGS; RATS; RATS, WISTAR; TRIGLYCERIDES; VALPROIC ACID;

EID: 38549101558     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.10.025     Document Type: Article

References (47)

1. Ettmayer P., Amidon G.L., Clement B., and Testa B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 47 10 (2004) 2393-2404
2. Han H.K., and Amidon G.L. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2 1 (2000) E6
3. Lambert D.M., Scriba G.K.E., Gallez B., Poupaert J.H., and Dumont P. Glyceride conjugates as drug carriers. Curr. Med. Chem. 1 5 (1995) 376-391
4. Scriba G.K., Lambert D.M., and Poupaert J.H. Bioavailability and anticonvulsant activity of a monoglyceride-derived prodrug of phenytoin after oral administration to rats. J. Pharm. Sci. 84 3 (1995) 300-302
5. Deverre J.R., Loiseau P., Couvreur P., Letourneux Y., Gayral P., and Benoit J.P. In-vitro evaluation of filaricidal activity of GABA and 1,3-dipalmitoyl-2-(4-aminobutyryl)glycerol HCl: a diglyceride prodrug. J. Pharm. Pharmacol. 41 3 (1989) 191-193
6. Lambert D.M. Rationale and applications of lipids as prodrug carriers. Eur. J. Pharm. Sci. 11 Supplement 2 (2000) S15-S27
7. Hostetler K.Y., Parker S., Sridhar C.N., Martin M.J., Li J.L., Stuhmiller L.M., van Wijk G.M., van den Bosch H., Gardner M.F., and Aldern K.A. Acyclovir diphosphate dimyristoylglycerol: a phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus. Proc. Natl. Acad. Sci. U. S. A. 90 24 (1993) 11835-11839
8. Kucera G.L., Goff C.L., Lyer N., Morris-Natschke S., Ishaq K.S., Wyrick S.D., Fleming R.A., and Kucera L.S. Cellular metabolism in lymphocytes of a novel thioether-phospholipid-AZT conjugate with anti-HIV-1 activity. Antivir. Res. 50 2 (2001) 129-137
9. Lalanne M., Paci A., Andrieux K., Dereuddre-Bosquet N., Clayette P., Deroussent A., Re M., Vassal G., Couvreur P., and Desmaele D. Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. Bioorg. Med. Chem. Lett. 17 8 (2007) 2237-2240
10. Ryu E.K., Ross R.J., Matsushita T., MacCoss M., Hong C.I., and West C.R. Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-d-arabinofuranosylcytosine 5′-monophosphate-l-1,2-dipalmitin and selected 1-beta-d-arabinofuranosylcytosine 5-diphosphate-l-1,2-diacylglycerols. J. Med. Chem. 25 11 (1982) 1322-1329
11. Sakai A., Mori N., Shuto S., and Suzuki T. Deacylation-reacylation cycle: a possible absorption mechanism for the novel lymphotropic antitumor agent dipalmitoylphosphatidylfluorouridine in rats. J. Pharm. Sci. 82 6 (1993) 575-578
12. van Wijk G.M., Hostetler K.Y., Kroneman E., Richman D.D., Sridhar C.N., Kumar R., and van den Bosch H. Synthesis and antiviral activity of 3′-azido-3′-deoxythymidine triphosphate distearoylglycerol: a novel phospholipid conjugate of the anti-HIV agent AZT. Chem. Phys. Lipids 70 2 (1994) 213-222
13. 2. Chem. Phys. Lipids 107 2 (2000) 143-157
14. Dahan A., Duvdevani R., Dvir E., Elmann A., and Hoffman A. A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J. Control. Release 119 1 (2007) 86-93
15. Dahan A., and Hoffman A. Mode of administration-dependent brain uptake of indomethacin: sustained systemic input increases brain influx. Drug Metab. Dispos. 35 2 (2007) 321-324
16. Dvir E., Elman A., Simmons D., Shapiro I., Duvdevani R., Dahan A., Hoffman A., and Friedman J.E. DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. CNS Drug Rev. 13 2 (2007) 260-277
17. Dvir E., Friedman J.E., Lee J.Y., Koh J.Y., Younis F., Raz S., Shapiro I., Hoffman A., Dahan A., Rosenberg G., Angel I., Kozak A., and Duvdevani R. A novel phospholipid derivative of indomethacin, DP-155, shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. J. Pharmacol. Exp. Ther. 318 3 (2006) 1248-1256
18. Friedman H.I., and Nylund B. Intestinal fat digestion, absorption, and transport. A review. Am. J. Clin. Nutr. 33 5 (1980) 1108-1139
19. Tso P. Gastrointestinal digestion and absorption of lipid. Adv. Lipid Res. 21 (1985) 143-186
20. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 51 1-2 (2002) 31-71
21. Labiner D.M. DP-VPA D-Pharm. Curr. Opin. Investig. Drugs 3 6 (2002) 921-923
22. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 43 1 (2001) 11-58
23. Isoherranen N., Yagen B., and Bialer M. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?. Curr. Opin. Neurol. 16 2 (2003) 203-211
24. Rosenberg G., Friedman J.E., Shapiro I., and Kozak A. DP-155. Drug Future 30 12 (2005) 1212-1218
25. Shackleford D.M., Porter C.J., and Charman W.N. In: Stella V.J., Borchardt R.T., Hageman M.J., Oliyai R., Maag H., and Tilley J.W. (Eds). Prodrugs: challenges and rewards (2007), AAPS press 653-682
26. Hoffman A., and Levy G. Kinetics of drug action in disease states. XXIX. Effect of experimental nephrotic syndrome on the pharmacodynamics of heptabarbital: implications of severe hypoalbuminemia. J. Pharmacol. Exp. Ther. 249 1 (1989) 117-122
27. Warshaw A.L. A simplified method of cannulating the intestinal lymphatic of the rat. Gut 13 1 (1972) 66-67
28. Dahan A., and Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur. J. Pharm. Sci. 24 4 (2005) 381-388
29. Kennedy B.P., Payette P., Mudgett J., Vadas P., Pruzanski W., Kwan M., Tang C., Rancourt D.E., and Cromlish W.A. A natural disruption of the secretory group II phospholipase A(2) gene in inbred mouse strains. J. Biol. Chem. 270 38 (1995) 22378-22385
30. Caliph S.M., Charman W.N., and Porter C.J. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J. Pharm. Sci. 89 8 (2000) 1073-1084
31. Khoo S.M., Edwards G.A., Porter C.J.H., and Charman W.N. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J. Pharm. Sci. 90 10 (2001) 1599-1607
32. O'Driscoll C.M. Lipid-based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 15 5 (2002) 405-415
33. Porter C.J., and Charman W.N. Intestinal lymphatic drug transport: an update. Adv. Drug Deliv. Rev. 50 1-2 (2001) 61-80
34. Gershkovich P., and Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur. J. Pharm. Sci. 26 5 (2005) 394-404
35. Nordskog B.K., Phan C.T., Nutting D.F., and Tso P. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv. Drug Deliv. Rev. 50 1-2 (2001) 21-44
36. Porter C.J., Trevaskis N.L., and Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6 3 (2007) 231-248
37. Dahan A., and Hoffman A. In: Touitou E., and Barry B.W. (Eds). Enhancement in drug delivery (2006), CRC press 111-127
38. Shackleford D.M., Faassen W.A., Houwing N., Lass H., Edwards G.A., Porter C.J.H., and Charman W.N. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J. Pharmacol. Exp. Ther. 306 3 (2003) 925-933
39. Garzon-Aburbeh A., Poupaert J.H., Claesen M., and Dumont P. A lymphotropic prodrug of l-dopa: synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)prop anoyl] propane-1,2,3-triol. J. Med. Chem. 29 5 (1986) 687-691
40. Garzon-Aburbeh A., Poupaert J.H., Claesen M., Dumont P., and Atassi G. 1,3-dipalmitoylglycerol ester of chlorambucil as a lymphotropic, orally administrable antineoplastic agent. J. Med. Chem. 26 8 (1983) 1200-1203
41. 2 enzymes. Prostaglandins Other Lipid Mediat. 68-69 (2002) 3-58
42. 2 enzymes: classification and characterization. Biochim. Biophys. Acta (BBA) 1488 1-2 (2000) 1-19
43. Tu B., and Bazan N.G. Hippocampal kindling epileptogenesis upregulates neuronal cyclooxygenase-2 expression in neocortex. Exp. Neurol. 179 2 (2003) 167-175
44. Visioli F., Rodriguez de Turco E.B., Kreisman N.R., and Bazan N.G. Membrane lipid degradation is related to interictal cortical activity in a series of seizures. Metab. Brain Dis. 9 2 (1994) 161-170
45. Kolko M., Christoffersen N., Varoqui H., and Bazan N.G. Expression and induction of secretory phospholipase A group IB in brain. Cell. Mol. Neurobiol. 25 7 (2005) 1107-1122
46. Friedman J.E., Schatz G., Armstrong H., White H.S., Wolf H.H., and Kozak A. DP-VPA, an efficacious, activity-dependent pro-drug of VPA. Annual Meeting of the American Epilepsy Society (1998) San Diego, CA
47. Dahan A., Mendelman A., Amsili S., Ezov N., and Hoffman A. The effect of general anesthesia on the intestinal lymphatic transport of lipophilic drugs: comparison between anesthetized and freely moving conscious rat models. Eur. J. Pharm. Sci. 32 4-5 (2007) 367-374